Trajan Group Holdings Ltd
ASX:TRJ
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| AU |
T
|
Trajan Group Holdings Ltd
ASX:TRJ
|
94.5m AUD |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
192.8B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
148.3B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
137.1T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
36.8B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
291.5B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
35.6B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
28.3B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28B USD |
Loading...
|
|
| CN |
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
164.6B HKD |
Loading...
|
Market Distribution
| Min | -6 907 100% |
| 30th Percentile | 21.6% |
| Median | 38.3% |
| 70th Percentile | 58.2% |
| Max | 2 095.9% |
Other Profitability Ratios
Trajan Group Holdings Ltd
Glance View
Trajan Group Holdings Ltd. engages in the designing, manufacturing and supply of products and solutions that enhance scientific measurement. The firm is developing and manufacturing analytical science instruments, devices and solutions used in the analysis of biological, food and environmental samples. The firm is focused on serving life science, biopharmaceutical, and analytical companies in the United States, Australia, Europe, and Asia. The firm is operating in two segments, which includes Analytical Products and Life Science Solutions. Its Analytical Products include Metal syringes, Gas tight syringes, eVol, liquid extraction (uLLE), Electrokinetic extraction (EkE), Ferrules, Microfluidics, Emitter tips, Septa and caps and Porous polymer monoliths. Its Life Science Solutions include Dispensing syringes, Microscope slides, Coverslips, Slide and cassette storage, Liquid powder dispensing, Infusion automation, hemaPEN, Microbiopsy and Hummingbird. The company also offers micro-biopsy device for skin sampling, including Mitra device.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Trajan Group Holdings Ltd is 37%, which is below its 3-year median of 39.3%.
Over the last 3 years, Trajan Group Holdings Ltd’s Gross Margin has decreased from 39.6% to 37%. During this period, it reached a low of 37% on Jun 30, 2025 and a high of 41.4% on Jun 30, 2023.
